TY - JOUR
T1 - Burkitt lymphoma after solid-organ transplant
T2 - Treatment and outcomes in the paediatric PTLD collaborative
AU - Afify, Zeinab
AU - Orjuela-Grimm, Manuela
AU - Smith, Christine Moore
AU - Dalal, Mansi
AU - Ford, James B.
AU - Pillai, Pallavi
AU - Robles, Joanna M.
AU - Reddy, Sonika
AU - McCormack, Sarah
AU - Ehrhardt, Matthew J.
AU - Ureda, Tonya
AU - Alperstein, Warren
AU - Edington, Holly
AU - Miller, Tamara P.
AU - Rubinstein, Jeremy D.
AU - Kavanaugh, Madison
AU - Bukowinski, Andrew J.
AU - Friehling, Erika
AU - Rivers, Julie M.
AU - Chisholm, Karen M.
AU - Marks, Lianna J.
AU - Mason, Clinton C.
N1 - Publisher Copyright:
© 2022 British Society for Haematology and John Wiley & Sons Ltd.
PY - 2023/2
Y1 - 2023/2
N2 - Burkitt lymphoma arising in paediatric post-solid-organ transplantation-Burkitt lymphoma (PSOT-BL) is a clinically aggressive malignancy and a rare form of post-transplant lymphoproliferative disorder (PTLD). We evaluated 35 patients diagnosed with PSOT-BL at 14 paediatric medical centres in the United States. Median age at organ transplantation was 2.0 years (range: 0.1–14) and age at PSOT-BL diagnosis was 8.0 years (range: 1–17). All but one patient had late onset of PSOT-BL (≥2 years post-transplant), with a median interval from transplant to PSOT-BL diagnosis of 4.0 years (range: 0.4–12). Heart (n = 18 [51.4%]) and liver (n = 13 [37.1%]) were the most frequently transplanted organs. No patients had loss of graft or treatment-related mortality. A variety of treatment regimens were used, led by intensive Burkitt lymphoma-specific French–American–British/Lymphomes Malins B (FAB/LMB), n = 13 (37.1%), and a low-intensity regimen consisting of cyclophosphamide, prednisone and rituximab (CPR) n = 12 (34.3%). Median follow-up was 6.7 years (range: 0.5–17). Three-year event-free and overall survival were 66.2% and 88.0%, respectively. Outcomes of PSOT-BL patients receiving BL-specific intensive regimens are comparable to reported BL outcomes in immunocompetent children. Multi-institutional collaboration is feasible and provides the basis of prospective data collection to determine the optimal treatment regimen for PSOT-BL.
AB - Burkitt lymphoma arising in paediatric post-solid-organ transplantation-Burkitt lymphoma (PSOT-BL) is a clinically aggressive malignancy and a rare form of post-transplant lymphoproliferative disorder (PTLD). We evaluated 35 patients diagnosed with PSOT-BL at 14 paediatric medical centres in the United States. Median age at organ transplantation was 2.0 years (range: 0.1–14) and age at PSOT-BL diagnosis was 8.0 years (range: 1–17). All but one patient had late onset of PSOT-BL (≥2 years post-transplant), with a median interval from transplant to PSOT-BL diagnosis of 4.0 years (range: 0.4–12). Heart (n = 18 [51.4%]) and liver (n = 13 [37.1%]) were the most frequently transplanted organs. No patients had loss of graft or treatment-related mortality. A variety of treatment regimens were used, led by intensive Burkitt lymphoma-specific French–American–British/Lymphomes Malins B (FAB/LMB), n = 13 (37.1%), and a low-intensity regimen consisting of cyclophosphamide, prednisone and rituximab (CPR) n = 12 (34.3%). Median follow-up was 6.7 years (range: 0.5–17). Three-year event-free and overall survival were 66.2% and 88.0%, respectively. Outcomes of PSOT-BL patients receiving BL-specific intensive regimens are comparable to reported BL outcomes in immunocompetent children. Multi-institutional collaboration is feasible and provides the basis of prospective data collection to determine the optimal treatment regimen for PSOT-BL.
KW - Burkitt lymphoma
KW - lymphoproliferative disorder
KW - post-solid-organ transplantation
UR - http://www.scopus.com/inward/record.url?scp=85143402577&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85143402577&partnerID=8YFLogxK
U2 - 10.1111/bjh.18498
DO - 10.1111/bjh.18498
M3 - Article
C2 - 36454546
AN - SCOPUS:85143402577
SN - 0007-1048
VL - 200
SP - 297
EP - 305
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 3
ER -